What's Happening?
Median Technologies has announced a strategic commercial partnership with Olea Medical, a subsidiary of Canon Medical Systems, to advance the deployment of eyonis® LCS, an AI-powered software for lung cancer screening. This partnership aims to accelerate
the adoption of eyonis® LCS across the United States and Europe, following its FDA clearance and CE marking. The software integrates detection and diagnosis within the lung cancer screening workflow, enhancing diagnostic confidence and efficiency. The collaboration is part of Median's strategy to expand its commercial ecosystem and improve early cancer detection.
Why It's Important?
Lung cancer is the deadliest cancer worldwide, accounting for 20% of all cancer-related deaths. Early diagnosis through low-dose CT screening can significantly improve patient outcomes. The partnership between Median Technologies and Olea Medical aims to address the unmet need in cancer screening by deploying AI-powered solutions that enhance early detection and diagnosis. This collaboration could set a new standard of care in lung cancer screening, potentially saving lives by enabling earlier intervention and treatment.
What's Next?
With regulatory authorizations secured, Median Technologies plans to convert these into commercial adoption of eyonis® LCS across major markets. The company intends to expand its network of partners to accelerate awareness and deployment of the software. This includes collaborations with healthcare technology players and imaging software companies to support lung cancer screening programs globally. The focus will be on establishing eyonis® LCS as a leading AI-based software for lung cancer screening.
